Vera Therapeutics to present IgA Nephropathy trial data at ASN Kidney Week
Vera Therapeutics will present the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy at ASN Kidney Week 2026. The presentation is scheduled as a late-breaking oral presentation during the opening plenary session.